Coherus Oncology, Inc.
CHRS
$1.20
$0.065.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 61.00% | 47.99% | 59.81% | -66.28% | -82.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.00% | 47.99% | 59.81% | -66.28% | -82.30% |
| Cost of Revenue | 37.22% | 50.64% | 58.29% | -86.17% | -90.44% |
| Gross Profit | 74.63% | 46.78% | 60.56% | 25.47% | -65.43% |
| SG&A Expenses | -19.95% | -16.44% | -16.52% | -21.35% | -26.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.59% | 2.42% | 1.47% | -32.01% | -41.68% |
| Operating Income | 15.92% | 5.73% | 6.67% | 13.78% | 3.41% |
| Income Before Tax | 13.34% | 11.88% | 15.45% | 26.89% | 23.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.34% | 11.88% | 15.45% | 26.89% | 23.22% |
| Earnings from Discontinued Operations | -92.07% | 452.16% | 43.28% | 35.30% | 71.82% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.51% | 242.26% | 489.41% | 34,538.00% | 712.65% |
| EBIT | 15.92% | 5.73% | 6.67% | 13.78% | 3.41% |
| EBITDA | 15.76% | 5.27% | 6.13% | 13.53% | 3.49% |
| EPS Basic | -166.87% | 246.99% | 445.44% | 17,176.92% | 582.47% |
| Normalized Basic EPS | 24.49% | 12.82% | 9.80% | 20.22% | 16.46% |
| EPS Diluted | -166.87% | 246.99% | 445.44% | 10,425.58% | 568.57% |
| Normalized Diluted EPS | 24.49% | 12.82% | 9.80% | 20.22% | 16.46% |
| Average Basic Shares Outstanding | 14.11% | 6.02% | 2.26% | 2.05% | 5.90% |
| Average Diluted Shares Outstanding | 14.11% | 6.02% | 2.26% | 2.05% | 5.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |